Kidney transplantation was the focus of numerous publications in 2016. Key studies demonstrated a survival advantage of HLA-incompatible kidney transplantation and suggested that novel approaches such as co-stimulation blockade using belatacept and treatment of antibody-mediated rejection using a C1 esterase inhibitor might prove to be future game changers.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ferrari, P. et al. Kidney paired donation: principles, protocols and programs. Nephrol. Dial. Transplant. 30, 1276–1285 (2016).
Orandi, B. J., Montgomery, R. A. & Segev, D. L. Kidney transplants from HLA-incompatible live donors and survival. N. Engl. J. Med. 375, 288–289 (2016).
Montgomery, R. A. et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am. J. Transplant. 16, 3468–3478 (2016).
Sautenet, B. et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 100, 391–399 (2016).
Vincenti, F. et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. 12, 210–217 (2012).
Pestana, J. O. et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am. J. Transplant. 12, 630–639 (2012).
Vincenti, F. et al. Belatacept and long-term outcomes in kidney transplantation. N. Engl. J. Med. 374, 2600–2601 (2016).
Gatault, P. et al. Reduction of extended-release tacrolimus dose in low immunological risk kidney transplant recipients increases risk of rejection and appearance of DSA — a randomized study. Am. J. Transplant. http://dx.doi.org/10.1111/ajt.14109 (2016).
Hricik, D. E. et al. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J. Am. Soc. Nephrol. 26, 3114–3122 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Malvezzi, P., Rostaing, L. Novel approaches to improve recipient and allograft outcomes. Nat Rev Nephrol 13, 73–74 (2017). https://doi.org/10.1038/nrneph.2016.190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.190
This article is cited by
-
CD39-adenosinergic axis in renal pathophysiology and therapeutics
Purinergic Signalling (2018)